News and Announcements
MedAdvisor Signs Agreement with Novartis Pharmaceuticals to Deliver Patient Engagement & Education Program
- Published May 30, 2016 12:05PM UTC
- Publisher Wholesale Investor
- Categories Company Updates
30th May 2016, ASX Announcement
Highlights:
- MedAdvisor signs a 12 month agreement with Novartis Pharmaceuticals Australia to deliver patient engagement and education program via the MedAdvisor platform
- Program will provide educational resources for patients, helping ensure they take their medications as prescribed to help improve patient adherence and quality use of medicines (QUMs)
- The program is to commence in June 2016 with three products initially and will run for 12 months
MedAdvisor Limited (ASX:MDR, the Company), Australia’s leading digital medication adherence company, is pleased to announce that it has signed a 12 month agreement to collaborate with Novartis Pharmaceuticals Australia.
To view the full announcement, please click on the button below.
Company Updates
From Desert to Dairy: How Australia’s Wild Camels and Good Earth Dairy’s Technology are Transforming Infant Formula
“In the heart of Australia’s outback, an innovative dairy company is harnessing the world’s largest wild camel population to revolutionise infant nutrition, targeting the rapidly growing AUD $127B global infant formula market with hypoallergenic solutions.
World-First FDA Approval for EBR Systems’ Leadless Cardiac Device Opens US$3.6bn Market
Discover how EBR Systems’ groundbreaking WISE CRT System, the first leadless left ventricular pacing technology, has gained FDA approval, addressing limitations of traditional cardiac resynchronisation therapy.
Half a Century in Bricks and Mortar: Industry Veteran Greg Paramor on Revealing Real Estate Opportunities in a Shifting Landscape
Veteran real estate leader Greg Paramor offers a grounded perspective on the Australian property market, highlighting the chronic undersupply and emerging opportunities for investors despite current economic headwinds.
Backed By Leading Investment Groups and Family Offices
